Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder
Brief Summary
The primary goal of this pilot study is to investigate whether psilocybin alters neuroplasticity in people with major depressive disorder. The primary hypothesis is that psilocybin will result in neuroplastic changes that parallel improvement in symptoms of depression.
Condition or Disease
- Major Depressive Disorder
Phase
Study Design
| Study type: | Interventional |
|---|---|
| Status: | Active, not recruiting |
| Study results: | No Results Available |
| Age: | 18 Years to 65 Years (Adult, Older Adult) |
| Enrollment: | 18 () |
| Funded by: | Other |
Masking |
|
Clinical Trial Dates
| Start date: | Jun 30, 2018 | |
|---|---|---|
| Primary Completion: | Jun 01, 2022 | |
| Completion Date: | Apr 01, 2023 | |
| Study First Posted: | Jun 13, 2018 | |
| Results First Posted: | Aug 30, 2020 | |
| Last Updated: | Nov 12, 2021 |
Sponsors / Collaborators
Lead Sponsor:
N/A
Responsible Party:
N/A
Location
In this placebo-controlled, blinded study, individuals with depression will participate in 2 experimental sessions approximately 4 weeks apart during which they will receive two of the following three interventions: 1) placebo, 2) low dose psilocybin (0.1 mg/kg), and 3) medium dose psilocybin (0.3 mg/kg).
Eligibility Criteria
| Sex: | All |
|---|---|
| Minimum Age: | 18 |
| Maximum Age: | 65 |
More Details
| NCT Number: | NCT03554174 |
|---|---|
| Other IDs: | 2000022394 |
| Study URL: | https://ClinicalTrials.gov/show/NCT03554174 |
Last updated: Jun 16, 2022